Mosaic Therapeutics
PrivateLast Round
Strategic
Apr 24, 2025
Total Funding Raised
$28M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Mosaic Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Strategic round in April 2025.
Mosaic Therapeutics is a biotechnology company that develops targeted oncology therapies for patient groups with unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mosaic Therapeutics Comparables
Compare Mosaic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enedra Therapeutics | 88% | |
| Evariste | 83% | |
| Eisbach Bio GmbH | 83% |
For institutional investors. Book with your work email.
Mosaic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Apr 24, 2025 | ||||
| Series A | Apr 4, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mosaic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cambridge Innovation Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors grew 191% MoM, reaching 1.6K.
- Jul 25, 2026
Monthly visitors grew 96% MoM, reaching 1.5K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 4, 2026
As of Aug 4th '26, Mosaic Therapeutics LTD develops ASTX295, a highly potent, clinical-stage, bone marrow-sparing MDM2 antagonist designed for combination use across haematological and solid cancers, with its first clinical combination study expected to commence in mid-2027.
- hiresAug 4, 2026
Mosaic Therapeutics LTD appoints Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development in United Kingdom on Aug 4th '26.
For institutional investors. Book with your work email.
Mosaic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mosaic Therapeutics's valuation, stock price, and market status.
Is Mosaic Therapeutics a public or private company?
Mosaic Therapeutics is a private company.
What is the current stock price of Mosaic Therapeutics?
Mosaic Therapeutics is a private company, so its shares have no public market price. Caplight tracks Mosaic Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mosaic Therapeutics worth (valuation)?
Valuation information for Mosaic Therapeutics is not publicly available.
Can I buy Mosaic Therapeutics stock?
Mosaic Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mosaic Therapeutics's last funding round?
Mosaic Therapeutics's most recent funding round was Strategic on April 24, 2025.
Who are the main investors in Mosaic Therapeutics?
Key investors in Mosaic Therapeutics include Cambridge Innovation Capital.
Will Mosaic Therapeutics IPO soon?
No public IPO plans have been announced for Mosaic Therapeutics.
How can I track Mosaic Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Mosaic Therapeutics's shares on secondary markets.